Trials / Completed
CompletedNCT04318093
Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure
A Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of BMS-986259 in Stabilized Patients Hospitalized for Acute Decompensated Heart Failure
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the safety of BMS-986259 in stable participants hospitalized for acute decompensated heart failure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986259 | Specified dose on specified days |
| OTHER | Placebo | Specified dose on specified days |
Timeline
- Start date
- 2020-11-06
- Primary completion
- 2021-07-19
- Completion
- 2021-07-19
- First posted
- 2020-03-23
- Last updated
- 2022-08-04
- Results posted
- 2022-08-04
Locations
18 sites across 6 countries: Argentina, Czechia, Greece, Israel, Poland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04318093. Inclusion in this directory is not an endorsement.